Monlunabant
Sources
registry, as of 2025-03-27Stale
https://clinicaltrials.gov/study/NCT05282446
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome. Overall status COMPLETED. Phases PHASE1. Lead sponsor Inversago Pharma Inc.. Enrollment 37. Conditions Metabolic Syndrome. INV-202-CL-105 is a phase 1B study to examine the safety and tolerability, as well as the pharmacokinetics (PK) pharmacodynamic (PD) effects of INV-202 in subjects with metabolic syndrome over 28 days.
ClinicalTrials.gov NCT05282446 protocol and results modules
registry, as of 2025-11-18Stale
https://clinicaltrials.gov/study/NCT06542536
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 73. Conditions Obesity. The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body. Oral monlunabant is a new medicine which cannot be prescr
ClinicalTrials.gov NCT06542536 protocol and results modules
registry, as of 2025-06-05Stale
https://clinicaltrials.gov/study/NCT05891834
Study of INV-202 in Patients With Obesity and Metabolic Syndrome. Overall status COMPLETED. Phases PHASE2. Lead sponsor Inversago Pharma Inc.. Enrollment 243. Conditions Obesity; Metabolic Syndrome. The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.
ClinicalTrials.gov NCT05891834 protocol and results modules
publication, as of 2025-10-16Stale
https://pubmed.ncbi.nlm.nih.gov/41038215/
metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, has shown encouraging weight loss efficacy and tolerability. We aimed to evaluate the efficacy and safety of monlunabant in individuals with obesity and metabolic syndrome. This
PMID 41038215